Progression free survival (PFS) and overall survival (OS) of patients treated with trastuzumab emtansine (T‑DM1) after previous treatment with pertuzumab in patients with advanced breast cancer (NCT02338167) - Schneeweiss, A; Lux, M P; Hartkopf, A D (2018)
Abstr. P6-17-22